Eisai has submitted a new drug application to Japan’s Pharmaceuticals and Medical Devices Agency for a subcutaneous ...

If approved, ReadyFlow Autoinjector would deliver an IV-equivalent diuretic dose (subcutaneous furosemide injection 80 mg/ml) in under 10 secondsWould potentially provide a cost-effective and ...

Eisai has submitted a new drug application to Japan’s PMDA seeking approval for Leqembi’s SC formulation, SC-AI, for early ...

The subcutaneous biologics market is driven by rising demand for targeted treatments, increasing self-administration methods, and technological innovations like encapsulation. North America leads the ...

Eisai seeks Japanese PMDA approval for subcutaneous formulation of Leqembi to treat early Alzheimer’s disease: Tokyo Monday, December 1, 2025, 14:00 Hrs [IST] Eisai Co., Ltd. an ...

Eisai files for Japan approval of a weekly at-home Leqembi injection, offering an alternative to IV dosing and aiming to ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...

The application is based on data from multiple subcutaneous (SC) administration sub-studies of lecanemab conducted as part of the Phase 3 Clarity AD open-label extension (OLE), following the 18-month ...

If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the ...

Merck & Co. has won European Commission approval of a formulation of its blockbuster cancer drug Keytruda that can be injected under the skin. The Rahway, N.J., drugmaker on Wednesday said the green ...

This marks the approval of the first and only subcutaneous immune checkpoint inhibitor in Europe that can be administered by a health care provider in as little as one minute “We are honored to ...